Syngenta Participations Ag

Sorrento Therapeutics, Inc.

Concortis Biosystems, Corp.

Pioneer Hi-Bred International, Inc.

The Scripps Research Institute

Chembridge Corporation

Apple Inc.

Boyce Thompson Institute for Plant Research

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Vivasor, Inc.

Concortis Biosystems, Corp., a Wholly Owned Subsidiary of Sorrento Therapeutics, Inc.

Abbvie Biotechnology Ltd

Tong Zhu

Zhenwei Miao

Yufeng Hong

Gang Chen

Xun Wang

Alisher B Khasanov

Joel Kreps

Bret Cooper

Hong Zhang

Alexander Chucholowski

Paul Budworth

Alexander Wilhelm Chucholowski

Sergey Zozulya

Christopher L Baszczynski

Steven P Briggs

Vlad Edward Gregor

Jason Conrad Pickens

Stephen Arthur Goff

Darrell Orlyn Ricke

Yahua Liu

Jeffrey F Harper

Alexey Vyacheslavovich Anikin

Charles Chamchoumis Mikel

Luyong Jiang

Zheng Yan

Douglas Eric McGrath

Todd Moughamer

Jane Glazebrook

Nicholas Provart

Benjamin A Bowen

Laura Ann Tagliani

David J Peterson

Gunnar F Kaufmann

Thomas R Webb

Rajendran Vairagoundar

Yanwen Fu

Fumiaki Katagiri

Vidyasagar Gantla

Mohan Santhanam Thiruvazhi

Bin Han

Devon L Brown

John H Duesing

Goverdhan Reddy Vavilala

Aleksander Kadushkin

Danny Peter Claude McGee

Sherman (Hur-Song) Chang

Heyue Zhou

John Dixon Gray

Sheng Zhang

Jingyi Wang

Pramod B Mahajan

Jin Li

Lichun Wang

Yan Zheng

Jing Wang

Wolfgang Fraunhofer

Giovanni Carbone

Hongmei Song

Tongtong Xue

Hong Zeng

Liang Xiao

Shengchang Cai

Peter B Kipp

Susan K Paulson

Sergey Sviridov

Markus Tschoepe

Lingyu Zhu

Gregory D May

Guanjun Tan

Henry Hongjun Ji

Carsten Weber

Heehyoung Lee

James T Patterson

Aditi G Kanhere

Tahereh Majdi

Liping Liu

Yan Qing

Dylan Deng

Alexander Kadushkin

Fumiyaki Katagiri

Guangzhou Zou

Hur-Song Chang

Yiping Fan

Fan Long

Katherine Fells

Laura Redden

Dylan Dalun Deng

Martin Gastens

Alexander Feick

Hong D Zhang

Li Yin

Qiuyan Yang

Qifeng Shi

Xi Zhao

Youngbae Son

Kyu Hyun Kim

Sijia Ma

An electronic device may have a display panel. Light from the display panel may be focused by a lens assembly towards a viewer. Optical crosstalk, off-axis color shift, and/or the presence of the lens assembly may cause color non-uniformity in images viewed through the lens assembly. To obtain color calibration information, first information may be used to simulate the color of the display panel when viewed through a lens assembly from a first number of points. The first information may include an average display panel color emission profile and a map of correlation between pixel locations and incident angles and corresponding pupil locations and gaze directions. The color of the display panel through the lens assembly may be measured at the first number of points to extract a lens non-uniformity contribution. The lens non-uniformity contribution may then be used to simulate color at a second, larger number of points.

Method of obtaining color calibration information for an electronic device

In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.

Drug-conjugates, conjugation methods, and uses thereof

There is disclosed an improved ADC (antibody drug conjugate) type composition having at least two different drug payloads conjugated to a single targeting protein. More specifically, the present disclosure attaches a first drug conjugate to a dual Cysteine residue on a targeting protein and a second drug conjugate with a different drug to a Lys residue on the targeting protein.

Drug-conjugates with a targeting molecule and two different drugs

Provided is a preparation method of an antibody-drug conjugate represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, or a solvate of the foregoing,

Anti-ErbB2 antibody-drug conjugate and composition thereof, preparation method therefor, and use thereof

There is disclosed an antibody drug conjugate (ADC) having an IgG antibody that binds to a CD38 target conjugated at a Cys site in the hinge region of an IgG antibody. There is further disclosed a method for treating multiple myeloma comprising providing an effective amount of a CD38 ADC.

CD38 antibody drug conjugate

There is disclosed derivatives of amanitin conjugated to a targeting antibody to form an ADC (antibody drug conjugate).

Antibody drug conjugates having derivatives of amatoxin as the drug

Provided herein are cell penetrating compounds having the Formula I: where, generally, each T is a thiol reactive group (e.g., a phosphorothioate), each L is a linker (e.g., a linear alkyl), and Y is a biologic (e.g., an antibody). Also provided are pharmaceutical compositions including the cell penetrating compounds, and methods of delivering the compound into a cell.

Cell internalizing compounds

Provided are bispecific conjugates having the general formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the treatment of cancer.

Disulfide bridging conjugates

There is disclosed a Dolastatin derivative, conjugated to an antibody, comprising a Dolastatin derivative moiety of Formula IV.

Antibody drug conjugates

In certain aspects, compounds and uses thereof are provided. In certain aspects, compound-conjugates and uses thereof are provided.

Provided are compounds of the formula (I): or a stereoisomer, tautomer, salt, hydrate or prodrug thereof that modulate tyrosine kinase activity, compositions comprising the compounds and methods of their use. 

Tyrosine kinase inhibitors

Growing community of inventors

San Diego, CA, United States of America

Tong Zhu